Atossa Therapeutics (NASDAQ:ATOS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report sent to investors on Monday, Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q3 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.21) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.18) EPS.

A number of other analysts have also weighed in on the company. Ascendiant Capital Markets raised their target price on Atossa Therapeutics from $6.00 to $6.25 and gave the company a buy rating in a research note on Thursday, June 6th. StockNews.com upgraded shares of Atossa Therapeutics from a sell rating to a hold rating in a research report on Tuesday, May 14th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th.

Atossa Therapeutics Trading Up 3.2 %

Shares of Atossa Therapeutics stock opened at $1.28 on Monday. The stock has a market capitalization of $160.97 million, a price-to-earnings ratio of -5.33 and a beta of 1.21. The firm’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.33. Atossa Therapeutics has a 1-year low of $0.62 and a 1-year high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities research analysts predict that Atossa Therapeutics will post -0.23 EPS for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares during the period. Renaissance Technologies LLC raised its stake in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after buying an additional 164,540 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Atossa Therapeutics by 3,160.5% during the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Rhumbline Advisers acquired a new position in Atossa Therapeutics in the second quarter valued at approximately $161,000. Finally, Virtu Financial LLC bought a new position in Atossa Therapeutics in the first quarter valued at approximately $151,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.